Abstracts tagged "autoimmune diseases"

Abstract Number: 2175 • 2016 ACR/ARHP Annual Meeting
Comparisons of Patients Prescribed Biosimilars or BIO-Originators for Autoimmune Diseases in Germany
Sumesh Kachroo¹, Christopher Black¹, Emma Sullivan², John Waller² and James Piercy², ¹CORE, Merck & Co., Inc., Kenilworth, NJ, ²Adelphi Real World, Manchester, United Kingdom
Background/Purpose: To compare the characteristics of patients who receive biosimilars against patients receiving bio-originators. Methods: The Adelphi Biosimilars Programme 2016 is a cross-sectional survey of…
Abstract Number: 2428 • 2016 ACR/ARHP Annual Meeting
Autoantibody Diversity in Pediatric Patients Undergoing Evaluation for Autoimmune Encephalitis: A Retrospective Investigation
Anne E Tebo¹, Thomas Haven², Aimee O. Hersh³ and Eyal Muscal⁴, ¹Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, UT, ²Department of Pathology, University of Utah, ARUP Institute of Clinical and Experimental Pathology, Salt Lake City, UT, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Immunology, allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Antibodies directed against N-methyl-D-aspartate type glutamate receptor (NMDAR), voltage-gated potassium channel (VGKC) or glutamic acid decarboxylase (GAD65) are frequently associated with autoimmune encephalitis (AE)…
Abstract Number: 2857 • 2016 ACR/ARHP Annual Meeting
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Jessica Schreiter¹, Jarrat Jordan¹, Matteo Cesaroni¹, Marc Chevrier², Alexa Piantone³, Ian Gourley³, Jacqueline Benson¹ and Takahiro Sato¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³Immunology Translational Medicine, Janssen Pharmaceutical Research and Development, LLC, Spring House, PA
Background/Purpose: Type I IFN (IFN-I)-regulated gene expression is known to be elevated in blood and skin lesions of patients with two different forms of cutaneous…
Abstract Number: 2927 • 2016 ACR/ARHP Annual Meeting
Mechanisms Regulating the Loss of Tregs in CD11c-Flip-KO Mice That Contribute to the Spontaneous Development of Inflammatory Arthritis
Qi Quan Huang¹, Renee E. Doyle², Robert Birkett¹, Deyu Fang³ and Richard M. Pope², ¹Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ²Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: CD11c-Flip-KO (HUPO) mice spontaneously develop inflammatory, erosive arthritis. We previously demonstrated that T regulatory cells (Tregs) were reduced in HUPO mice and that the…
Abstract Number: 280 • 2015 ACR/ARHP Annual Meeting
The Fascia Is a Target Organ of Inflammation in Autoimmune Diseases
Kentaro Noda, Ken Yoshida, Taro Ukichi, Kazuhiro Furuya, Kenichiro Hirai, Isamu Kingetsu and Daitaro Kurosaka, Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: We previously reported that inflammation occurred early in the fascia of patients with dermatomyositis. We often encounter patients with autoimmune diseases who present with…
Abstract Number: 3158 • 2015 ACR/ARHP Annual Meeting
Impact of Family History of Systemic Lupus Erythematosus on Risk of Autoimmune Diseases: National Cohort Study in Denmark 1977-2012
Constance Jensina Ulff-Møller¹, Jacob Simonsen², Søren Jacobsen¹ and Morten Frisch², ¹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease (AID), which develops through the interplay of genetic, epigenetic and environmental factors and may cluster…
Abstract Number: 387 • 2015 ACR/ARHP Annual Meeting
Features of 847 Childhood-Onset Systemic Lupus Erythematousus Patients in Three Age-Related Groups at Diagnosis: A Brazilian Multicenter Study
Clovis A Silva¹, Roberta C. Gomes Sr.², Marco F. Silva³, Katia T. Kozu⁴, Eloisa Bonfá⁵, Rosa M R Pereira⁶, Maria Teresa Terreri⁷, Claudia S. Magalhães Sr.⁸, Silvana B. Sacchetti Sr.⁹, Roberto Marini Sr.¹⁰, Melissa Fraga¹¹, Luciana M. Carvalho Sr.¹², Cássia M. Barbosa¹³ and Magda Carneiro-Sampaio Sr.¹⁴, ¹Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit-Children’s Institute,, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Pediatrics, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Pediatrics, Universidade Federal de Sao Paulo, São Paulo, Brazil, ⁸Pediatric Rheumatology Unit, São Paulo State University – Faculdade de Medicina de Botucatu, São Paulo, Brazil, ⁹Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ¹⁰Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ¹¹Pediatrics, Universidade Federal de São Paulo / UNIFESP, São Paulo, Brazil, ¹²Pediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, São Paulo, Brazil, ¹³Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, ¹⁴Pediatric Allergology and Immunology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Previous retrospective evaluations suggested that age at diagnosis may influence disease expression in terms of initial clinical presentation, pattern of organ involvement and serological…
Abstract Number: 826 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis Inpatient Mortality Has Not Improved from 1995-2011. Results from a National Irish Audit of Scleroderma Co-Morbidities.
Len Harty¹, Deirdre Fitzgerald², Michael Henry², John Ryan³ and Sinead Harney³, ¹Cork University Hospital, Cork, Ireland, ²Respiratory, Cork University Hospital, Cork, Ireland, ³Rheumatology, Cork University Hospital, Cork, Ireland
Background/Purpose: Despite the advent of potent immunosuppressive and vasoactive therapies it is not clear that longevity of patients with systemic sclerosis (SSc) has improved. Therefore…
Abstract Number: 1033 • 2015 ACR/ARHP Annual Meeting
Novel Ligand-Independent Peptide Inhibitors of Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and T Cell Receptor (TCR): Efficacy in a Collagen-Induced Arthritis Model Suggests New Targeted Treatment for Rheumatoid Arthritis
Zu T. Shen and Alexander B. Sigalov, SignaBlok, Inc., Shrewsbury, MA
Background/Purpose: Macrophages and T cells are central to the pathophysiology of autoimmune diseases. Synovial macrophages, synovial fibroblasts and infiltrating T lymphocytes are the most abundant…
Abstract Number: 1224 • 2015 ACR/ARHP Annual Meeting
Infection Rate in HIV Patients Who Received TNF-a Inhibitor Therapy for Concomitant Autoimmune Diseases
Sintawat Wangsiricharoen¹, Colin Ligon², Ahmad Dehrab³, Lydia Gedmintas⁴, Marisa Tungsiripat⁵, Clifton Bingham⁶, Carlos J. Lozada⁷ and Leonard H. Calabrese⁸, ¹Chiang Mai University, Chiang Mai, Thailand, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, University of Miami Jackson Memorial Hospital, Miami, FL, ⁴Rheumatology, Brigham's Women's Hospital, Boston, MA, ⁵Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Miami Miller School of Medicine, Miami, FL, ⁸Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Few HIV-infected patients have been treated with tumor necrosis factor (TNF)-α inhibitor therapy for autoimmune diseases refractory to conventional therapies. Evidence supporting the safety…
Abstract Number: 1356 • 2015 ACR/ARHP Annual Meeting
Autoimmune Manifestations in Hepatitis C: A Single-Centered Experience
Azza Ali¹, Reshma Khan¹, Kirthi Lilley², Paul Naylor², Rajaie Namas¹ and Malini Venkatram¹, ¹Rheumatology, Wayne State University, Detroit, MI, ²Gastroenterology, Wayne State University, Detroit, MI
Background/Purpose: Hepatitis C infection (HCV) is a leading cause of chronic liver disease. It is associated with a plethora of autoimmune manifestations including clinical, serological…
Abstract Number: 1416 • 2015 ACR/ARHP Annual Meeting
Postoperative Complications Rate in Orthopaedic Surgery Performed in Rheumatic Patients in Use of Biologic Agents
Clarissa Queiroz Pimentel¹, Luiz Eduardo de Paula¹, Ana Paula Luppino-Assad², Gilberto Luis Camanho³, Eloisa Bonfá⁴ and Marco Antonio Gonçalves Pontes Filho¹, ¹Division of Rheumatology, University of São Paulo Medical School, São Paulo, Brazil, ²Division of Rheumatology, University of São Paulo, sao paulo, Brazil, ³Division of Orthopedics, University of São Paulo Medical School, São Paulo, Brazil, ⁴Rheumatology, University of São Paulo, São Paulo, Brazil, Sao Paulo, Brazil
Background/Purpose: Biologic agents have been associated with an increased risk of infection, thrombosis and delayed wound healing. However, there is no definitive consensus on suspension…
Abstract Number: 1512 • 2015 ACR/ARHP Annual Meeting
Incidence of Co-Morbid Autoimmune Diseases in Patients with Rheumatoid Arthritis
TA Simon¹, H Kawabata¹, JM Esdaile², V Moorthy³ and S Suissa⁴, ¹Bristol-Myers Squibb, Hopewell, NJ, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Mu Sigma, Northbrook, IL, ⁴McGill University, Montreal, QC, Canada
Background/Purpose: Rheumatoid arthritis (RA) is one of more than 80 different types of autoimmune diseases, many of which, including RA, share common pathogenic mechanisms, resulting…
Abstract Number: 1762 • 2015 ACR/ARHP Annual Meeting
Reciprocal Roles of Intestinal Microbiota in the Pathogenesis of Organ-Specific Autoimmune Diseases in a Lymphopenia-Induced Autoimmunity Mouse Model
Toshiki Eri¹, Kimito Kawahata², Ei Bannai¹, Takeyuki Kanzaki³, Lisa Akahira¹, Kazuya Michishita¹ and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ³Internal Medicine, Yamanashi Prefectural Central Hospital, Yamanashi, Japan
Background/Purpose: Past studies reported lymphopenia mouse transfer model which transfer CD4+CD25- cells from wild-type BALB/c mouse into athymic nude BALB/c mice produce lupus-like systemic autoantibodies…
Abstract Number: 1937 • 2015 ACR/ARHP Annual Meeting
Dalazatide (ShK-186), a First-in-Class Blocker of Kv1.3 Potassium Channel on Effector Memory T Cells: Safety, Tolerability and Proof of Concept of Immunomodulation in Patients with Active Plaque Psoriasis
Ernesto J. Munoz-Elias¹, David Peckham¹, Kayla Norton¹, Judilyn Duculan², Inna Cueto², Xuan Li³, James Qin⁴, Kurt Lustig⁵, Eric Tarcha¹, Jared Odegard⁴, James G. Krueger² and Shawn P. Iadonato¹, ¹Kineta Inc, Seattle, WA, ²Rockefeller University, New York, NY, ³Rockefeller University, New York, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Kineta Inc., Seattle, WA
Background/Purpose: Effector memory T cells of both CD4 and CD8 lineages are key drivers of autoimmunity and are pathogenic in several autoimmune diseases including psoriasis,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].